英夫利昔治疗溃疡性结肠炎临床疗效的荟萃分析  

The efficacy of Infliximab in the treatment of ulcerative colitis:a meta-analysis

作　　者：夏璐[1] 王正廷[1] 李晓露[1] 冯燕君[1] 程吉华[1] 戴欣[1] 刘慧黎[1] 钟捷[1] 

机构地区：[1]上海交通大学附属瑞金医院消化科,上海200025

出　　处：《胃肠病学和肝病学杂志》2012年第7期632-636,共5页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的采用荟萃分析的方法,探讨英夫利昔(Infliximab,IFX)治疗溃疡性结肠炎(ulcerative colitis,UC)的疗效。方法全面检索并收集研究IFX治疗UC的临床随机对照试验。纳入7篇文献,共有7个随机对照实验(RCT)。质量评价、独立提取资料后以RevMan 4.2分析。结果荟萃分析显示:比较IFX与安慰剂治疗UC的长期、短期疗效,结果均有显著差异。比较IFX 5 mg、10mg与安慰剂组短期、长期的疗效,结果有显著差异。IFX的短期及长期疗效与激素相比,结果无显著差异。IFX与安慰剂的不良反应结果无显著差异。结论 IFX可以诱导UC的临床缓解及维持,而且对于难治性中重度UC,IFX可以使患者减少结肠切除率,提高生活质量。但是仍然需要大样本多中心的随机对照试验来进一步验证。Objective To analyze the efficacy and safety of Infliximab in treatment of ulcerative colitis （UC）. Methods Randomized controlled trials of IFX in patients with UC were searched by electronic retrieve and hand re- trieve. Seven studies and seven RCTs were enrolled into the analysis. The information of the trial design, characters of the subjects, results of the studies were analyzed by Revman 4.2 software. Results The long-term and short-term effects in IFX group were significantly different compared with the control group. The long-term and short-term effects in IFX 5 mg/kg group and IFX 10 mg/kg group were significantly different compared with the control group. There was no differ- ence in long-term and short-term effect between IFX group and control group. There was no difference in side effect of medicine between IFX group and control group. Conclusion Infliximab could not only maintain the clinical remission in UC patients, but also decrease the colon resection rate for patients with moderate to severe refractory UC. It could also improve the life qualities. RCT of multiplicity centers is necessary to confirm the conclusion with large samples.

关 键 词：英夫利昔 溃疡性结肠炎 荟萃分析 

分 类 号：R574.62[医药卫生—消化系统]